Papillary Thyroid Carcinoma

• CLINICAL_TRIALS approval · 2025-01-17
  Clinical Trial Update: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

  Eli Lilly's RET inhibitor selpercatinib (Retevmo) has been approved for marketing to treat cancers driven by RET activation, including non-s…

• FDA approval · 2024-04-10
  FDA Approved: RETEVMO — Supplemental Application (Eli Lilly and Company)

  FDA approved a supplemental application for RETEVMO (selpercatinib) from Eli Lilly, expanding its labeled indications for RET fusion–positiv…

• FDA approval · 2020-05-08
  FDA Approved: RETEVMO — Original Application (Eli Lilly and Company)

  FDA approved Retevmo (selpercatinib) from Eli Lilly in its original NDA. The approval covers RET fusion-positive non-small cell lung cancer …